Janssen Presents Efficacy And Subgroup Analyses From MAIA Study Showing Long-Term Results Of DARZALEX (daratumumab)-based Regimen In Newly Diagnosed, Transplant-Ineligible Multiple Myeloma
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new analyses from the Phase 3 MAIA study of DARZALEX® (daratumumab) in combination with lenalidomide and dexamethasone (D-Rd), evaluating
